10. YHN Acquisition I Ltd ($YHNAU)

YHN Acquisition I Ltd. (YHNAU) is a special purpose acquisition company (SPAC) that completed its initial public offering (IPO) on September 18, 2024, raising $60 million by offering 6 million units at $10 per unit. Each unit comprises one ordinary share and a right to receive one-tenth of an ordinary share upon completing a business combination. The company, led by CEO Satoshi Tominaga, plans to pursue mergers or acquisitions across any industry or geographic location​(Nasdaq)​(Stock Titan).

9. Cayson Acquisition Corp ($CAPNU)

Cayson Acquisition Corp raised $60 million through its IPO on September 20, 2024, offering 6 million units at $10 each. This SPAC is listed on NASDAQ Global under the ticker CAPNU and aims to merge with a target company in an industry yet to be identified. As a blank-check company, Cayson has the flexibility to explore opportunities across various sectors and regions. The management team behind Cayson Acquisition has extensive experience in identifying high-growth businesses, which makes the SPAC an attractive vehicle for companies looking to go public quickly. The proceeds from the IPO will be used to search for and acquire a business that aligns with Cayson’s growth objectives​(Nasdaq)

8. Guardian Pharmacy Services, Inc. ($GRDN)

Guardian Pharmacy Services raised $112 million in its IPO on September 26, 2024, offering 8 million shares at $14 each. Listed on the NYSE under the ticker GRDN, Guardian is a leading provider of specialized pharmacy services for long-term care facilities, including nursing homes, assisted living, and behavioral health communities. The company focuses on delivering medication management solutions that improve patient safety and reduce medication errors. Guardian operates a network of locally managed pharmacies across the United States, providing personalized services tailored to the needs of each facility. With the capital raised from its IPO, Guardian plans to expand its reach, enhance its technology offerings, and further solidify its position as a leader in the long-term care pharmacy space​​(Nasdaq).

7. MBX Biosciences, Inc. ($MBX)

MBX Biosciences raised $163.2 million through its IPO on September 13, 2024, by offering 10.2 million shares at $16 each. MBX is listed on the NASDAQ Global Select under the ticker MBX and is a clinical-stage biotech company focused on developing therapies for rare endocrine diseases. The company’s lead candidate is designed to address disorders caused by deficiencies in certain hormones, with an initial focus on rare growth disorders. MBX leverages its expertise in endocrine biology to develop precision therapies that aim to restore normal hormone function in patients. The funds from the IPO will be used to advance the clinical trials of its lead drug candidate and expand its research and development efforts into additional endocrine disorders (Nasdaq).

6. BioAge Labs, Inc. ($BIOA)

BioAge Labs raised $198 million in its IPO on September 26, 2024, offering 11 million shares at $18 each. Listed on the NASDAQ Global Select under the ticker BIOA, BioAge is a biotechnology company focused on targeting the biology of aging to develop therapeutics that extend a healthy lifespan. The company uses advanced machine learning and human longevity data to discover novel drug targets that could treat age-related diseases. Its lead candidates aim to address conditions like muscle loss, cognitive decline, and immune system aging. BioAge Labs' approach is distinct in that it seeks to directly modulate biological pathways associated with aging, rather than treating the symptoms of aging-related diseases. With the proceeds from its IPO, BioAge plans to advance its drug candidates through clinical trials and continue expanding its discovery platform (Nasdaq).

5. Andretti Acquisition Corp. II ($POLEU)

Andretti Acquisition Corp. II raised $200 million through its IPO on September 6, 2024, offering 20 million units at $10 each. Listed on the NASDAQ Global under the ticker POLEU, this SPAC is focused on identifying merger targets within the automotive, motorsports, and related industries. The company is backed by Andretti Autosport, a legendary name in the world of racing, which provides it with unique insight into the motorsports industry. Andretti Acquisition Corp. II is positioned to leverage its expertise to identify cutting-edge companies in vehicle technology, electric vehicles, and other growth areas within the automotive sector. The $200 million raised will allow Andretti to pursue mergers or acquisitions that capitalize on emerging technologies in automotive innovation (Nasdaq).

4. Vine Hill Capital Investment Corp. ($VCICU)

Vine Hill Capital Investment Corp. raised $200 million through its IPO on September 6, 2024, by offering 20 million units at $10 each. This special purpose acquisition company (SPAC) is listed on the NASDAQ Global under the ticker VCICU. Vine Hill is focused on identifying and merging with a target company, with a flexible mandate that spans across multiple industries and geographies. The SPAC is particularly interested in companies with strong growth potential and experienced management teams. Its leadership includes seasoned investors with a track record of successful acquisitions, making it well-positioned to identify high-value targets. SPACs like Vine Hill are designed to offer private companies a faster route to public markets, and with $200 million in capital, the company is poised to execute a significant acquisition (Nasdaq).

3. Zenas BioPharma, Inc. ($ZBIO)

Zenas BioPharma raised approximately $225 million during its IPO on September 13, 2024, by offering 13.2 million shares at $17 each. The company, listed on the NASDAQ Global Select under the ticker ZBIO, specializes in developing novel immunotherapies for autoimmune and rare diseases. Zenas is focused on leveraging its deep expertise in immune modulation to create therapies that restore immune balance. Its lead drug candidates are aimed at treating conditions like systemic lupus erythematosus and autoimmune thyroid diseases. The company’s pipeline includes several therapies that are in various stages of development, with the potential to address significant unmet needs in both rare and more common autoimmune conditions. With the proceeds from its IPO, Zenas BioPharma aims to accelerate the development of its clinical pipeline and bring these life-changing treatments closer to patients​ (Nasdaq).

2. BKV Corp ($BKV)

BKV Corp raised $270 million through its IPO on September 26, 2024, offering 15 million shares at $18 each, and is now listed on the NYSE under the ticker BKV. As a key player in the natural gas sector, BKV focuses on producing and marketing natural gas with a commitment to sustainability and reducing carbon emissions. The company is primarily involved in the extraction and distribution of clean energy solutions from natural gas fields, helping to bridge the gap between traditional fossil fuels and greener alternatives. BKV is also investing in technologies aimed at improving the efficiency of natural gas usage, positioning itself as a major player in the ongoing energy transition. With the funds from its IPO, BKV plans to expand its production capabilities and further develop sustainable practices (Nasdaq).

1. Bicara Therapeutics Inc. ($BCAX)

Bicara Therapeutics raised $315 million in its IPO on September 13, 2024, by offering 17.5 million shares at $18 each. The company, listed on the NASDAQ Global under the ticker BCAX, focuses on developing innovative bifunctional therapies aimed at treating solid tumors. Its lead program, ficerafusp alfa, is designed to block both EGFR and TGF-β, two clinically validated cancer targets. This dual-targeting mechanism is expected to have potent anti-tumor effects by simultaneously inhibiting cancer cell growth and reducing immunosuppressive signaling in the tumor microenvironment. Bicara’s therapies are particularly promising for hard-to-treat cancers like head and neck squamous cell carcinoma, where there is significant unmet need. With this IPO, Bicara is well-positioned to advance its clinical trials and bring transformative cancer treatments to market​(Bicara Therapeutics Inc.)​(Pharmaceutical Technology)​(Bicara Therapeutics Inc.).